Vous n'êtes pas connecté
The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. HEIDELBERG/PARIS, June 3rd 2024 – BioMed X, an independent German biomedical research institute, and Servier, an international independent pharmaceutical company, announce the start of a new research team at the […]
Research focused on collecting and analysing plants native to Ethiopia is showing promise against cervical cancer cells. Thanks to a new...
A recent study by the Helmholtz Institute Erlangen-Nuremberg, which is based at Forschungszentrum Jülich, has developed an efficient and...
The head of Applied Pharmaceutical Innovation said a new manufacturing facility and start-up incubator that the company is building at the Edmonton...
Research from Colorado State University uses stem cells to study neuronal connections and communication, potentially aiding in the development of...
GBP34000 - GBP40000 per year: Immunocore: Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company whose...
A University of Wollongong project has been awarded a $565,193 grant to develop a new manufacturing process for a component in hydrogen fuel cells....
US Biomedical Advanced Research and Development Authority funds will be used to complete the development and testing of a mRNA-based vaccine for bird...
USask spearheads cutting-edge research. SASKATOON — University of Saskatchewan (USask) researchers Dr. Changiz Taghibiglou (PhD) and Dr. Sara...